Drug/Small Molecule:
methoxyflurane

2D structure

Overview

Generic Names: MOF; Methoflurane; Methoxiflurane; Methoxifluranum; Methoxyfluoran; Methoxyfluorane; Methoxyfluran; Methoxyfluranum [INN-Latin]; Metossiflurano [Dcit]; Metoxfluran; Metoxifluran; Metoxiflurano [INN-Spanish]
Trade Names: Analgizer; Anecotan; Ingalan; Inhalan; Methofane; Methoxane; Metofane; Penthrane; Pentran; Pentrane
PharmGKB Accession Id: PA450434

Description

An inhalation anesthetic. Currently, methoxyflurane is rarely used for surgical, obstetric, or dental anesthesia. If so employed, it should be administered with nitrous oxide to achieve a relatively light level of anesthesia, and a neuromuscular blocking agent given concurrently to obtain the desired degree of muscular relaxation. (From AMA Drug Evaluations Annual, 1994, p180) (source: Drug Bank)

Indication

For use in the induction and maintenance of general anesthesia (source: Drug Bank)

ATC Therapeutic Category

  • N01AB:Halogenated hydrocarbons

Pharmacology, Interactions, and Contraindications

Mechanism Of Action

Methoxyflurane induces a reduction in junctional conductance by decreasing gap junction channel opening times and increasing gap junction channel closing times. Methoxyflurane also activates calcium dependent ATPase in the sarcoplasmic reticulum by increasing the fluidity of the lipid membrane. It also appears to bind the D subunit of ATP synthase and NADH dehydogenase. Methoxyflurane also binds to the GABA receptor, the large conductance Ca<sup>2+</sup> activated potassium channel, the glutamate receptor and the glycine receptor. (source: Drug Bank)

Pharmacology

Methoxyflurane is a general inhalation anesthetic used for induction and maintenance of general anesthesia. It induces muscle relaxation and reduces pains sensitivity by altering tissue excitability. It does so by decreasing the extent of gap junction mediated cell-cell coupling and altering the activity of the channels that underlie the action potential. (source: Drug Bank)

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Hepatic. (source: Drug Bank)

Toxicity

LD<sub>50</sub>=3600 mg/kg (Orally in rats). Symptoms of overexposure include eye irritation, CNS depression, analgesia, anesthesia, seizures, respiratory depression, and liver and kidney damage. (source: Drug Bank)

Isomeric SMILES Code:

COC(C(Cl)Cl)(F)F (source: Drug Bank)

A list of non-curated publications that mention this drug along with other genes is available.

Drug Targets

Gene Description
ATP5D Uncurated Annotation (source: Drug Bank)
ATP2C1 Uncurated Annotation (source: Drug Bank)
CYB5A Uncurated Annotation (source: Drug Bank)
GABRA1 Uncurated Annotation (source: Drug Bank)
GRIA1 Uncurated Annotation (source: Drug Bank)
GLRA1 Uncurated Annotation (source: Drug Bank)
MT-ND1 Uncurated Annotation (source: Drug Bank)
KCNA1 Uncurated Annotation (source: Drug Bank)

A list of non-curated publications that mention this drug along with other drugs is available.

Non-Curated Information

A list of non-curated publications that mention this drug along with other diseases is available.

LinkOuts

Web Resource:
Wikipedia
DrugBank:
DB01028
KEGG Compound ID:
C07517
KEGG Drug ID:
D00544
PubChem Compound ID:
4116
PubChem Substance ID:
149389

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Non-Curated Publications

A list of non-curated publications that mention this drug is available.

PharmGKB integrates drug information from different sources: DrugBank, Open Eye Scientific Software.
Add New Alternate Name
Add New ATC Term
Add Cross Reference
Add a metabolite
Add a text annotation
Add a drug target
hint: enter a gene
    Add a drug interaction
    hint: enter a drug
    PharmGKB® is a registered trademark of HHS and is financially supported by NIH/NIGMS. It is managed at Stanford University (GM61374).
    ©2001-2010 PharmGKB.